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Abstract
Background: Myelin oligodendrocyte glycoprotein immunoglobulin G1 (MOG-IgG1)-associated disease is
suggested as a separate disease entity distinct from multiple sclerosis and neuromyelitis optica spectrum disorder.
Nonetheless, the optimal treatment regimen for preventing relapses in MOG-IgG1-associated disease remains unclear.
Case presentation: We describe the case of a 45-year-old man with MOG-IgG1-positive highly relapsing optic neuritis
who had experienced 5 attacks over 21 months and had monocular blindness despite prednisolone and
azathioprine therapy. He began treatment with rituximab, which reduced the rate of relapse markedly. Following
discontinuation of rituximab, however, the patient experienced two successive optic neuritis attacks 2 and 4
months after B-lymphocyte restoration.
Conclusions: Highly relapsing MOG-IgG1-associated disease can be prevented with rituximab even when the
MOG-IgG1 titers are relatively stationary. Discontinuation of rituximab and restoration of B-lymphocytes may be
associated with the rebound of disease activity.
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Background
Myelin oligodendrocyte glycoprotein immunoglobulin
G1 (MOG-IgG1)-associated disease is suggested as a
separate disease entity distinct from multiple sclerosis and
neuromyelitis optica spectrum disorder (NMOSD) with
anti-aquaporin-4 IgG (AQP4-IgG); it has a predilection
for the optic nerve rather than spinal cord, perineural
enhancement extending to adjacent soft tissues on mag-
netic resonance imaging (MRI), and a less unfavorable
prognosis than NMOSD [1]. Recent studies with a suffi-
cient number of patients and duration of follow-up have
indicated that a considerable number of patients with
MOG-IgG1 have relapsing attacks in the central nervous
system followed by neurological deficits [2, 3]. Nonethe-
less, the optimal treatment regimen for preventing
relapses in patients with MOG-IgG1-associated disease
has only recently begun to be studied [4]. Here, we de-
scribe a patient with highly relapsing optic neuritis (ON)
associated with MOG-IgG1, whose ON attacks were
relatively well-prevented with rituximab (RTX) treatment.
However, the patient experienced rebounds of repeated
ON attacks shortly after the restoration of B-cells follow-
ing discontinuation of RTX.
Case presentation
A 45-year-old man presented with decreased right visual
acuity (VA) accompanied by periocular pain lasting for 1
week. Ophthalmological examination revealed that the
patient’s right eye was only able to perceive light (best-
corrected VA, light perception/0.9 in decimals, measured
using a Snellen chart) and had relative afferent pupillary
defect of grade 3, diffuse disc swelling, and inferior disc
hemorrhage. Neurological examination showed normal
muscle strength in all extremities, no sensory deficits,
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normoactive deep tendon reflexes, and no signs of bladder
or bowel dysfunction. Orbit MRI revealed T2 high signal
intensities and diffuse contrast enhancement along the
right anterior and posterior optic nerve, as well as peri-
neural enhancement [1] (Fig. 1-a and b). The results of
cerebrospinal fluid (CSF) analysis showed a red blood cell
count of 0/μL, a white blood cell count of 1/μL, and a pro-
tein level of 27mg/dL. CSF oligoclonal band measured by
isoelectric focusing was negative and IgG index was 0.64.
The result of a serum AQP4-IgG flow cytometry assay
using AQP4-M23-expressing live cells was negative [5].
Right ON was suspected, and intravenous methylprednis-
olone (1000mg pulse therapy) for 5 days followed by oral
prednisolone (60mg daily) were prescribed. The right VA
of the patient was improved to 0.5 (visual Functional
System score improved to 2 from 5).
The second right ON attack (0.15/1.0) occurred 4
months after the first ON when the prednisolone dose
had been tapered to 10mg daily. Thus, azathioprine 50
mg twice per day was started in a remission state
between the second and third ON (4 months prior to
the third ON). The average thickness of a retinal nerve
fiber layer measured by spectral-domain optical coher-
ence tomography was decreased in the right eye (right
51 μm and left 105 μm) (Fig. 2-a). The third (hand move-
ment/0.9) and fourth (finger count/1.2) right ON attacks
occurred 6 and 10months after the second ON, respect-
ively, while the prednisolone dose was maintained at 5
mg daily and azathioprine was 75 mg twice per day.
Following these attacks, the patient developed left cen-
tral serous chorioretinopathy (0.15/0.9) associated with
long-term steroid use. The 25mg dose of prednisolone
was thus tapered out at this point. Nevertheless, right
ON recurred 2 months later for a fifth time (hand move-
ment/0.9) when the patient was under azathioprine
treatment only. At this time, the patient developed
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Fig. 1 (a) Axial and (b) coronal T1-weighted magnetic resonance images demonstrating diffuse gadolinium enhancement and swelling along the
right anterior and posterior optic nerve. c Longitudinal clinical course of recurrent optic neuritis. d Change of CD19+ B-lymphocytes (%) during
rituximab treatment. e Change of MOG-IgG1 titers measured by a geometric mean fluorescence (G-mean) ratio of the MOG-expressing cells that
bound to IgG1 using in-house flow cytometry (G-mean ratio = G-mean values of the patient’s sera / G-mean values of the healthy control)
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monocular blindness. The pattern-reversal visual evoked
potential showed an abnormal waveform in the right eye
with diminished amplitude. The left eye presented a
relatively preserved response with prolonged P100 la-
tency (118 ms) (Fig. 2-b). Serum from the patient
sampled at the time of the fifth ON attack was tested for
MOG-IgG1 using a cell-based assay utilizing full-length
human MOG (Radcliffe Hospital, Oxford, UK) [6]. The
result of this test was positive.
Despite continued immunosuppressive treatment and
due to the repeated ON attacks and the side effect of the
steroid (chorioretinopathy), the patient was administered
RTX (375mg/m2, 3 weekly infusion for induction and 3
maintenance doses under CD19+ B-cell monitoring over
29 months). Although one mild ON attack (no light
perception/1.2) occurred in the patient’s right eye during
RTX treatment, the rate of relapse decreased markedly
and the patient’s visual function was well-maintained.
However, 32 months after the initiation of RTX treat-
ment, we became unable to maintain RTX treatment
due to insurance issues (denial for reimbursement). As a
result, the treatment was switched to mycophenolate
mofetil (250 mg twice per day) combined with oral pred-
nisolone (5 mg every other day). The patient’s CD19+
B-lymphocyte level was restored to 2 and 4% at 9 and
11months after the last RTX infusion, respectively. Sub-
sequently, 2 more left ON attacks (hand movement/1.0
and hand movement/0.15) occurred within a one-month
interval (Fig. 1-c and 1-D). The titer of MOG-IgG1 was
measured by a geometric mean fluorescence (G-mean)
A
B = 118 ms
Fig. 2 a (Remission state after the second optic neuritis) the average retinal nerve fiber layer thickness measured by spectral-domain optical
coherence tomography was decreased in the right eye (right 51 μm and left 105 μm), with preferential thinning of the superior, temporal, and
inferior quadrants. b (During fifth optic neuritis) the pattern-reversal visual evoked potential showed an abnormal waveform in the right eye with
diminished amplitude. The left eye presented a relatively preserved response with prolonged P100 latency (118 ms)
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ratio of the MOG-expressing cells bound to IgG1 using
in-house flow cytometry. The G-mean ratio was calcu-
lated for each sera as followings: G-mean values of the
patient’s sera / G-mean values of the healthy control.
The titer was not associated with the continuation or
cessation of the RTX treatment (Fig. 1-e).
Discussion and conclusions
Here, we describe the longitudinal clinical course and
treatment response to RTX therapy in a patient with
MOG-IgG1-positive highly relapsing ON. We found that
1) highly relapsing MOG-IgG1-associated disease can be
prevented with RTX even when the MOG-IgG1 titers
are relatively preserved, and 2) discontinuation of RTX
in patients with this condition can cause rebound of
disease activity with restoration of B-lymphocytes.
Initial reports regarding MOG-IgG1-associated disease
indicated that it typically has a monophasic and benign
disease course [7]. However, recent multicenter studies
have shown that a considerable proportion of patients
have a relapsing course of disease, and some have signifi-
cant neurological deficits [2, 3]. More recently, RTX was
reported to reduce the rate of relapse in some cases of
MOG-IgG1-associated disease [4]. Nevertheless, the re-
sults of studies comparing the patient’s condition before
vs. after the treatment should be interpreted with cau-
tion because the disease may have a naturally decreasing
relapse rate in the later stages, as in NMOSD [8], and
also the statistical phenomenon of regression towards
the mean. In this regard, the present case, wherein we
observed a restoration of B-lymphocytes and a subse-
quent rebound of relapses after discontinuation of RTX
treatment, implies that long-term RTX maintenance
therapy may be helpful in patients with highly relapsing
MOG-IgG1-associated disease.
Despite initial treatment with azathioprine and prednis-
olone, the patient had a high relapse rate of 0.238/year (5
attacks over 21months) and subsequent unilateral visual
loss in the right eye. After initiating RTX treatment, his
relapse rate markedly decreased to 0.031/year (1 attack
over 32months). However, the patient experienced 2 ON
attacks over 4months following cessation of RTX treat-
ment and restoration of B-lymphocytes.
In summary, the case described here illustrates that
RTX can be a good treatment option for preventing
relapses in MOG-IgG1-associated disease. The treatment
effect was observed despite the relatively unchanged
MOG-IgG1 titers during the treatment period. Finally,
cessation of RTX treatment and restoration of B-lympho-
cytes may be associated with the rebound of disease activ-
ity. RTX may serve as an effective treatment regimen in
MOG-IgG1-associated disease, especially in patients with
high relapse rates.
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